Navigation Links
Genomic Health Announces First Quarter 2008 Financial Results and Business Progress
Date:5/6/2008

ned an expanded coverage policy from WellPoint, Inc., a leading

health benefits provider, to include the majority of women diagnosed

with node-negative, estrogen receptor-positive breast cancer.

International

-- Established exclusive marketing agreement with GeneKor to distribute

Oncotype DX in Greece.

-- Expanded partnership with Teva Pharmaceutical Industries Ltd. to

include distribution of Oncotype DX in Turkey.

Pipeline

-- Studies presented at the American Society of Clinical Oncology's

Gastrointestinal Cancers Symposium in January identified genes that

could help predict the likelihood of recurrence and chemotherapy

benefit for early-stage (stage II and III) colon cancer.

-- Based on multiple clinical studies and analysis, reached a key

milestone with the finalization of an 18-gene panel for our Oncotype DX

colon cancer assay, which is now undergoing analytical validation. The

company anticipates beginning a clinical validation study of the assay

in the second half of 2008.

-- Announced plans to evaluate the use of the Oncotype DX 21-gene breast

cancer panel, and also seek to identify other genes that may be used

for treatment planning in women with ductal carcinoma in situ, or DCIS,

which affects approximately 60,000 women per year in the United States.

-- Under our collaboration with Pfizer, we received our first payments for

the initiation of research to develop a genomic test to estimate the

risk of recurrence following surgery for patients with stage I-III

renal carcinoma, clear cell type.

Conference Call Details

To access the live conference call today, May 6 at 4:30 p.m. Eastern Time via phone, please dial (877) 356-8064 from the United States and Canada or (706) 758-4314 internationally. The conference ID is 45418205. Please dial in appr
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
3. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
4. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
7. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
8. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, ... Company Limited (Biohaven), announced today that dosing has ... a glutamate modulating agent. Biohaven filed an investigational ... clearance from the U.S. Food and Drug Administration ... 54% equity interest in Biohaven, a private company. ...
(Date:8/27/2015)... , Aug. 27, 2015 HUYA Bioscience ... meeting of the Japan Society of HTLV-1, held this ... Auditorium. The purpose of the Society is to promote ... the development of medical technology and research related to ... welfare. "HUYA is proud to support this ...
(Date:8/27/2015)... , Aug. 27, 2015 In response ... FedEx, UPS and The US Postal Service to ... classified as ,select agents, by the CDC, Marken ... handling these sensitive shipments. Marken uses ... regulations, trained and certified personnel to ensure the ...
(Date:8/26/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, today announced that ... & Company Emerging Growth Conference on September 2 at ... New York Marriott Marquis. A live ... investor relations section of Roka Bioscience,s website at ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... DIEGO, Aug. 24, 2011 Biocept, Inc., a privately-held ... analysis of circulating tumor cells (CTCs) in cancer patients, ... a collaboration on the commercialization of a proprietary blood ... the determination of HER2 status.  Clarient and Biocept will ...
... PARIS and MINNEAPOLIS, Aug. 24, 2011 Cellectis ... subsidiary of Cellectis (Alternext: ALCLS), and Recombinetics, a ... entered a development and license agreement on the ... creates, in accordance with biosafety and animal well-being ...
... United Therapeutics Corporation (NASDAQ: UTHR ... Phase 3 trial of treprostinil diethanolamine (oral treprostinil), ... a stable synthetic form of prostacyclin, in patients ... that the trial did not achieve statistical significance ...
Cached Biology Technology:Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients 2Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients 3Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients 4Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 2Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 3FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 2FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 3FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 4
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... arrhythmia a chronic irregularity of heartbeat which ... the condition is not acutely life-threatening, it does increase ... cardiac insufficiency, stroke and dementia. In the third of ... of researchers, led by LMU physician PD Dr. Stefan ...
... SAN DIEGO - Some say the world,s population will ... will present significant challenges for agriculture to provide enough ... scientist Rod Hill., Hill and Larry Branen, a University ... American Association for the Advancement of Science annual meeting ...
... hunger could be large over the next 20 years, according ... temperatures could significantly reduce yields of wheat, rice and maize ... who subsist on less than $1 a day. The resulting ... drive many into poverty. But even as some people ...
Cached Biology News:When the heart gets out of step 2When the heart gets out of step 3Biotech, nanotech and synthetic biology roles in future food supply explored 2Global warming may hurt some poor populations, benefit others 2Global warming may hurt some poor populations, benefit others 3Global warming may hurt some poor populations, benefit others 4
E2F2 protein...
Anti-DDDDK-Tag (Enterokinase Cleavage Site), Agarose Conjugate Research Focus: tag Storage: 4C Shipping Temperature: 4C...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Biology Products: